Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Immune profiling of smoldering myeloma patients treated with vaccine targeting XBP1/CD138/CS1 + HDACi citarinostat +/- len finds more B intermediate, CD8 effector memory and B memory cells, fewer plasmablasts and CD4 prolif. cells.”

“Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide”

Authors: Diana Cirstea, Rajib Shome, Mehmet Samur, Srikanth Talluri, Joseph Connolly, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul Richardson, Noopur Raje et al.

Myeloma Paper of the Day, April 29th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.